Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Impact · against what's priced in

Aldeyra Therapeutics faces a catastrophic valuation reset following the FDA's refusal to approve its lead drug, reproxalap, and a subsequent 70% stock price collapse. The initiation of a securities fraud investigation by Johnson Fistel adds a layer of legal liability to an already devastated pipeline.

ALDX−1.00

No priced-in read yet